This study underscores the generally grave prognosis for patients with adenoid cystic carcinoma of the lacrimal gland and the difficulty in making any conclusive recommendations for local therapy for this disease.

No abstract

Our experience suggests that lymphoscintigraphy and SLN biopsy with a small volume of technetium Tc-99m sulfur colloid and small incisions, even without the use of the blue dye, can identify SLNs in patients with conjunctival and eyelid malignancies, and can be performed safely.

<H4>BACKGROUND AND OBJECTIVE</H4> <P>An observational case series to assess the value of positron emission tomography (PET) in staging ocular adnexal lymphomas and evaluating their response to therapy.</P> <H4>PATIENTS AND METHODS</H4> <P>The clinical records of 16 consecutive patients with ocular adnexal lymphoma for whom pretreatment and posttreatment PET scans and corresponding computed tomography (CT) and magnetic resonance imaging (MRI) scans were available were compared.</P> <H4>RESULTS</H4> <P>Pretreatment PET scans demonstrated fluorine 18-fluorodeoxyglucose (FDG) positive lesions in 15 orbits of 12 patients. In 1 patient with low-grade follicular lymphoma of the orbit, PET revealed an additional focus of lymphoma in the deltoid muscle that was missed on clinical examination and conventional radiography. All of the posttreatment PET scans showed complete resolution of FDG uptake, suggesting good response to therapy. However, posttreatment CT and MRI scans demonstrated residual masses in 3 patients.</P> <H4>CONCLUSIONS</H4> <P>PET is valuable for initial staging of ocular adnexal lymphomas and may be a good adjunct to conventional imaging in evaluation of response to therapy.</P> <P>[<CITE>Ophthalmic Surg Lasers Imaging</CITE> 2007;38:319-325.]</P> <H4>AUTHORS</H4> <P>From the Department of Nuclear Medicine (IG); the Section of Ophthalmology (MFE, RD, BE); and the Department of Lymphoma and Myeloma (PM, BP), The University of Texas M. D. Anderson Cancer Center, Houston, Texas.</P> <P>Accepted for publication January 9, 2007.</P> <P>Address correspondence to Bita Esmaeli, MD, Section of Ophthalmology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 441, Houston, TX 77030.</P>

No abstract